Wenyuan Xiong
Overview
Explore the profile of Wenyuan Xiong including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
78
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Xiong W, Hietala S, Nyberg J, Papasouliotis O, Johne A, Berghoff K, et al.
Cancer Chemother Pharmacol
. 2022 Jun;
90(1):53-69.
PMID: 35771259
Purpose: Tepotinib is a highly selective MET inhibitor approved for treatment of non-small cell lung cancer (NSCLC) harboring METex14 skipping alterations. Analyses presented herein evaluated the relationship between tepotinib exposure,...
2.
Xiong W, Papasouliotis O, Jonsson E, Strotmann R, Girard P
Cancer Chemother Pharmacol
. 2022 Apr;
89(5):655-669.
PMID: 35385993
Purpose: Tepotinib is a highly selective, potent, mesenchymal-epithelial transition factor (MET) inhibitor, approved for the treatment of non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping. Objectives of this...
3.
Grisic A, Xiong W, Tanneau L, Jonsson S, Friberg L, Karlsson M, et al.
Clin Cancer Res
. 2021 Dec;
28(7):1363-1371.
PMID: 34921021
Purpose: Empirical time-varying clearance models have been reported for several immune checkpoint inhibitors, including avelumab (anti-programmed death ligand 1). To investigate the exposure-response relationship for avelumab, we explored semimechanistic pharmacokinetic...
4.
Tsimberidou A, Shaw J, Juric D, Verschraegen C, Weise A, Sarantopoulos J, et al.
J Hematol Oncol
. 2021 Aug;
14(1):127.
PMID: 34407844
Background: The PI3K/AKT/mTOR (PAM) pathway is a key regulator of tumor therapy resistance. We investigated M2698, an oral p70S6K/AKT dual inhibitor, in patients with advanced cancer who failed standard therapies....
5.
Xiong W, Friese-Hamim M, Johne A, Stroh C, Klevesath M, Falchook G, et al.
CPT Pharmacometrics Syst Pharmacol
. 2021 Apr;
10(5):428-440.
PMID: 33818908
Tepotinib is a highly selective and potent MET inhibitor in development for the treatment of patients with solid tumors. Given the favorable tolerability and safety profiles up to the maximum...
6.
Falchook G, Kurzrock R, Amin H, Xiong W, Fu S, Piha-Paul S, et al.
Clin Cancer Res
. 2019 Dec;
26(6):1237-1246.
PMID: 31822497
Purpose: Tepotinib is an oral, potent, highly selective MET inhibitor. This first-in-man phase I trial investigated the MTD of tepotinib to determine the recommended phase II dose (RP2D). Patients And...